US Corporate Distress Financial Stress SEC Filings — July 06, 2026

06-07-2026

Extra Space Storage Inc. completed a public offering of $550M in 4.900% Senior Notes due 2032, with proceeds used for general corporate purposes. The notes are guaranteed by the company and certain subsidiaries, and rank equally with existing senior unsecured debt but are structurally subordinated to secured debt. The offering was priced at 99.702% of par, and the notes mature on February 1, 2032.

• · The notes are governed by a base indenture dated May 11, 2021, as supplemented by a sixteenth supplemental indenture dated July 6, 2026.
• · Interest is payable semi-annually on February 1 and August 1, beginning February 1, 2027.
• · The issuer may redeem the notes at any time at the greater of 100% of principal or a make-whole premium, plus accrued interest; after January 1, 2032, redemption price is 100% of principal plus accrued interest.
• · Events of default include failure to pay interest for 30 days, failure to pay principal when due, failure to comply with other agreements for 60 days after notice, failure to pay other debt over $100M, and bankruptcy events.
• · The offering was made under an effective shelf registration statement (No. 333-278690) filed April 15, 2024.

06-07-2026

On June 29, 2026, Trafalgar Asset Management, LLC, controlled by Porfirio Sanchez Talavera, acquired 100% of the Series A and Series B Preferred Stock of The Greater Cannabis Company, Inc., gaining approximately 96.62% of the aggregate voting power. Concurrently, certain company indebtedness was canceled and extinguished via Debt Cancellation and Release Agreements. Porfirio Sanchez Talavera was appointed CEO and Chairman, while former CEO Aitan Zacharin resigned from all officer positions and will depart the board after a 10-day period.

• · Former CEO Aitan Zacharin's resignation was not due to any disagreement with the company regarding operations, policies, or practices.
• · Porfirio Sanchez Talavera's Trafalgar Asset Management has completed transactions exceeding $2.5 billion in aggregate value.
• · Trafalgar Digital was sold to Walmart de México y Centroamérica in April 2023.
• · Aitan Zacharin facilitated an eight-figure buyout offer from Teladoc for Mediconecta.
• · The company is in final stages of regulatory approval for a 100-patient Phase 2 clinical study for autism-related spectrum disorders.

06-07-2026

BioXcel Therapeutics entered into the Tenth Amendment to its Credit Agreement with Oaktree-led lenders, capitalizing accrued interest and deferring a $9.0M principal and interest payment from June 30 to July 31, 2026. The amendment reduces the minimum liquidity covenant from $12.5M to $7.5M, but requires the company to secure a definitive transaction by July 31, 2026 that repays all obligations or provides alternative capital. The company also agreed to form a strategic process committee with exclusive authority over restructuring or sale, and imposed strict negative covenants, including a compensation freeze and bi-weekly cash flow reporting, reflecting significant financial distress.

• · The company paid a fee of 100 basis points (1.00%) of the outstanding principal amount, paid in kind by adding to principal.
• · The company is prohibited from entering into, terminating, or modifying compensation arrangements with directors, officers, or employees through July 31, 2026.
• · Disbursements for any two-week period cannot exceed 115% of the aggregate budgeted amount for that period.
• · The company must hold weekly meetings with lenders and financial advisors and deliver a 13-week cash flow budget bi-weekly.
• · The company agreed to waive any restrictions on lenders assigning their interests to third parties.

06-07-2026

Unum Group announced a $3.8 billion long-term care (LTC) reinsurance transaction with Fortitude Re, covering 26% of total LTC statutory reserves and 52% of individual LTC reserves as of March 31, 2026. Combined with a prior 2025 transaction, cumulative LTC statutory reserve reduction reaches approximately 40%. The transaction is expected to close in 2026, with Unum maintaining a strong capital position and unchanged capital deployment priorities.

• · Unum will retain administration of the reinsured business, including claims handling and premium rate increase program management.
• · Fortitude Re will retrocede biometric risk on the reinsured block to a highly rated global reinsurer.
• · Transaction is expected to be funded through a combination of Fairwind excess capital, holding company liquidity, and financing related to future tax benefits.
• · Year-end 2026 holding company liquidity expected to be $1.5 billion to $2.0 billion.
• · Transaction's impact on operating earnings is expected to be limited to foregone investment income and incremental interest expense associated with transaction financing.
• · Conference call scheduled for July 6, 2026 at 8:00 a.m. ET.

06-07-2026

Big Digital Energy (BGDE) announced a 50/50 joint venture with 10NetZero to acquire a power-ready 50-acre site in Hood County, Texas, for AI datacenter development. The site currently has 17 MW of operational power, expandable to 111 MW of grid power (subject to ERCOT validation) and up to 311 MW with behind-the-meter natural gas generation. The acquisition would increase BGDE's total operational capacity from 129 MW to 146 MW, but the deal is subject to a letter of intent and closing conditions, with no definitive agreement yet in place.

• · The site has over 30,000 square feet of existing structures to be repurposed for datacenter use and an administrative office as a Command Center.
• · Two 12-inch and one 20-inch natural-gas pipelines provide option for behind-the-meter generation.
• · Northland Capital Markets engaged as financial advisor for AI/HPC evaluation and site-level financing.
• · Company is actively evaluating expansion opportunities within its current powered land portfolio and potential acquisitions from an affiliate of its executive management team.
• · The deal is currently only a letter of intent; no definitive agreement has been signed, and closing conditions remain.

06-07-2026

UBUYHOLDINGS INC filed an 8-K on July 6, 2026, reporting material modifications to security holder rights (Item 3.03), amendments to its articles of incorporation or bylaws (Item 5.03), and the results of a shareholder vote (Item 5.07). The filing is informational and multi-item, but no specific financial metrics, transaction values, or guidance were disclosed. The absence of quantitative data limits the ability to assess materiality or directional impact.

• · Filing date: July 6, 2026
• · AccNo: 0001829126-26-007292
• · File size: 986 KB
• · Items reported: 3.03, 5.03, 5.07, 9.01
• · No financial statements or exhibits were described in the summary

06-07-2026

Avnet Inc. and its subsidiary Avnet Receivables Corporation entered into Amendment No. 9 to their Fourth Amended and Restated Receivables Purchase Agreement, dated July 1, 2026, with a syndicate of financial institutions led by Wells Fargo Bank, N.A. as Agent. The amendment updates the facility commitments, reallocates purchaser interests, and extends the receivables purchase program, with total commitments of $700 million across five financial institutions. No financial performance metrics or period-over-period comparisons are provided in this filing.

• · The amendment was executed on July 1, 2026, and filed on July 6, 2026.
• · The original agreement was dated August 16, 2018, and has been amended nine times.
• · The facility is governed by New York law and includes a waiver of jury trial.
• · Conditions for effectiveness included receipt of executed counterparts, a Purchaser Fee Letter, a legal opinion, and representations that no Amortization Event or Potential Amortization Event exists.

06-07-2026

ITG, Inc. filed an Amended and Restated Certificate of Incorporation on July 6, 2026, reclassifying its existing common stock into a dual-class structure with 1 billion Class A shares and 200 million Class B shares, and authorizing 5 million preferred shares. The Class B shares are non-dividend, non-liquidating, and subject to strict transfer restrictions, tied one-to-one to Common Units in ITG Parent LLC. This restructuring appears to consolidate control among existing LLC owners while providing a path for Class B holders to exchange their units for Class A shares.

• · The reclassification was effective upon filing with the Delaware Secretary of State on July 6, 2026.
• · Each share of Old Common Stock (par value $0.01) was automatically reclassified into one share of Class A Common Stock.
• · Class B Common Stock can only be issued to and held by Permitted Class B Owners (Existing Opco LLC Owners and their Permitted Transferees).
• · Class B shares carry one vote per share but no dividend rights and no liquidation rights.
• · Class B shares are subject to strict transfer restrictions; any transfer in violation is void and the shares become non-voting.
• · The Company must reserve sufficient Class A shares to exchange all outstanding Common Units (excluding those held by the Company).
• · Preferred Stock terms are to be fixed by the Board at issuance.

06-07-2026

FreeCast, Inc. (CAST) announced a $23.7 million private placement of common stock and pre-funded warrants to new institutional and existing long-term investors. The offering, expected to close on July 2, 2026, will provide working capital and general corporate purposes. While the financing strengthens the company's financial foundation, it also dilutes existing shareholders and the securities are not initially registered under the Securities Act.

• · Pre-funded warrants have an exercise price of $0.0001 per share and do not expire until exercised.
• · The offering is exempt from registration under Section 4(a)(2) of the Securities Act and/or Regulation D.
• · FreeCast has agreed to file a resale registration statement with the SEC covering the shares sold in the offering.
• · The company's technology integrates live TV, streaming services, on-demand programming, free ad-supported channels, and digital media into a unified interface.

06-07-2026

Mitesco, Inc. (MITI) secured a $30 million equity line of credit from longtime investor C/M Capital Partners, L.P., intended to fund strategic technology acquisitions and accelerate growth in data center, AI, and real estate software verticals. The facility supplements $10 million in existing obligations and carries a 10% market discount pricing with a 2% fee. However, the company faces dilution risk from the discounted equity issuance, and its past healthcare business activities remain a drag, as some funds may be used to retire bridge debt and historical obligations.

• · The equity line of credit allows Mitesco to draw funding on its own schedule over up to 36 months.
• · Pricing for stock issued is generally at a 10% discount to market, subject to adjustment under certain conditions.
• · The company expects to file a registration statement shortly to make shares free-trading.
• · Some funding may be allocated to retiring bridge debt and historical obligations from the now-discontinued healthcare business.
• · The company's investor contact is Jimmy Caplan (512) 329-9505 / jimmycaplan@me.com; company contact is Brian Valania (610) 888-7509 / bvalania@centcoreusa.com.

06-07-2026

Bain Capital Private Credit, as servicer, and its subsidiary BCPC II-J, LLC, as borrower, entered into a Second Amendment to their Loan and Security Agreement dated June 30, 2026. The amendment modifies terms of the original agreement from August 21, 2024, with JPMorgan Chase as administrative agent and Deutsche Bank entities as collateral agent, administrator, and securities intermediary. The filing does not disclose specific financial figures or performance metrics, so no period-over-period comparisons are available.

• · The amendment was entered into among BCPC II-J, LLC as borrower, Bain Capital Private Credit as servicer, JPMorgan Chase as administrative agent, and Deutsche Bank entities as collateral agent, collateral administrator, and securities intermediary.
• · Effectiveness of the amendment is conditioned on delivery of executed signature pages, payment of outstanding fees per the Amended and Restated Administrative Agency Fee Letter, delivery of an enforceability opinion from counsel, and receipt of organizational certificates.
• · The amendment modifies the Loan and Security Agreement originally dated August 21, 2024, with changes reflected in Exhibit A attached to the filing.

06-07-2026

T. Rowe Price OHA Select Private Credit Fund issued $400M in 6.500% Notes due 2031, raising net proceeds of approximately $391.4M. The notes are unsecured and rank pari passu with existing unsecured debt but junior to secured obligations. Proceeds will be used for investments, reducing borrowings, and general corporate purposes.

• · The Notes mature on July 2, 2031, and interest is payable semi-annually on January 2 and July 2, commencing January 2, 2027.
• · The Fund may redeem the Notes in whole or in part at any time at redemption prices set forth in the Indenture.
• · The Indenture includes covenants requiring compliance with asset coverage requirements under the Investment Company Act of 1940, even if the Fund is no longer subject to those requirements.
• · Upon a change of control repurchase event, the Fund must offer to repurchase the Notes at 100% of principal plus accrued interest.
• · The Notes were offered under Rule 144A and Regulation S, and have not been registered under the Securities Act.
• · The Fund entered into a Registration Rights Agreement obligating it to file an exchange offer registration statement or a shelf registration statement for the Notes.

06-07-2026

Scilex Holding Company announced a binding term sheet for a $100 million strategic investment from iHolding Group LLP, a Kazakhstan-based private investment group. The investment, at $15.00 per share for approximately 6.67 million shares, is intended to support growth initiatives including product development, commercialization, and acquisitions. However, the transaction remains subject to due diligence, definitive agreements, board and stockholder approvals, and regulatory clearances, creating execution risk.

• · iHolding Group LLP is headquartered in Almaty, Republic of Kazakhstan, and focuses on healthcare, technology, and cross-border strategic investments.
• · The proposed investment is one of the largest Kazakhstan-origin healthcare investments into a U.S.-listed biopharmaceutical company in recent years.
• · Scilex's commercial products include ZTlido®, ELYXYB®, and Gloperba®; pipeline candidates include SP-102 (SEMDEXA™), SP-103, and SP-104.
• · The transaction requires approval from Scilex's stockholders and any required regulatory approvals.

06-07-2026

USA Compression Partners, LP filed a Certificate of Formation with the Texas Secretary of State to convert from a Delaware limited partnership to a Texas limited partnership, effective July 6, 2026. The conversion is a redomestication move, with the general partner remaining USA Compression GP, LLC and the principal office unchanged in Dallas, Texas.

• · The converting entity was originally formed as a Delaware limited partnership on June 7, 2011.
• · The conversion is effective at 12:01 a.m. Central Time on July 6, 2026.
• · The registered agent is Corporation Service Company d/b/a CSC-Lawyers Incorporating Service Company, located at 211 East 7th Street, Suite 620, Austin, TX 78701.
• · The principal office address remains 8117 Preston Road, Suite 300, Dallas, TX 75225.

06-07-2026

ProFrac Holding Corp. completed the refinancing of its asset-based lending facility, replacing a $275 million facility with a new $300 million revolving credit facility from Eclipse Business Capital LLC, which matures in July 2030. The new facility provides improved borrowing base terms, increased liquidity, and an extended maturity profile, while also including an uncommitted accordion feature allowing for up to $325 million in total commitments. The refinancing was executed to repay the prior facility and support the company's strategic initiatives.

• · The Eclipse ABL Credit Facility is secured by first-priority liens on current asset collateral and second-priority liens on fixed asset collateral.
• · Borrowings bear interest at Adjusted Term SOFR plus 4.25% until January 1, 2027, then at Base Rate plus 3.00%-3.50% or Adjusted Term SOFR plus 4.00%-4.50% based on availability and a fixed charge coverage ratio pricing grid.
• · The credit agreement contains customary events of default including nonpayment, material inaccuracy of representations, covenant defaults, cross-defaults, insolvency, judgments, ERISA events, and change of control.
• · During an event of default, the interest rate may increase by 2.00%.
• · Moelis & Company LLC acted as exclusive placement agent, and Gibson, Dunn & Crutcher LLP as legal counsel.

06-07-2026

Greenpro Capital Corp. (GRNQ) raised $100,000 in gross proceeds through a private placement of 65,591 shares of common stock at $1.5246 per share, sold to its CEO, President and Director, Mr. Lee Chong Kuang. The offering closed on June 30, 2026, and proceeds will be used for operating capital. Following the transaction, Mr. Lee and his spouse hold an aggregate of 2,106,799 shares, representing approximately 11.62% of the outstanding common stock.

• · The offering was made under exemptions from registration provided by Section 4(a)(2) of the Securities Act and Regulation D and/or Regulation S.
• · No underwriters were involved in the offering.
• · The per share purchase price was $1.5246.
• · The filing was made on July 6, 2026, reporting the event that occurred on June 30, 2026.

06-07-2026

iPower Inc. (IPW) announced it secured a $2.0 million convertible note investment from an institutional investor, providing unrestricted growth capital to advance AI, supply chain infrastructure, and other strategic initiatives. Management views the financing as a vote of confidence in its strategy to drive revenue growth and profitability, though the amount is relatively modest for a publicly traded company.

• · The financing is unrestricted, giving iPower full discretion to deploy capital toward high-priority opportunities.
• · The company is expanding into AI infrastructure investments and related financing ecosystems beyond its established e-commerce operations.
• · iPower seeks to participate in the growth of compute, data center, and infrastructure layers that support artificial intelligence.

06-07-2026

Fathom Holdings Inc. (FTHM) amended the Equity Purchase Agreement for the sale of Dagley Insurance Agency, deferring a $3.0 million payment due May 3, 2026 into three installments: $985,000 (paid prior to June 30), $1,000,000 (paid July 1, 2026), and $1,015,000 (due September 1, 2026). In exchange, Nathan Dagley agreed to cancel 278,000 shares of FTHM common stock, and both parties provided mutual releases of claims. The amendment also extends the Seller Affiliates Obligation to introduce clients to Dagley Insurance through May 2, 2028, subject to a service standard.

• · The amendment was effective as of June 30, 2026.
• · Interest accrues at 1.50% per month on any unpaid installment amounts.
• · The Seller is entitled to recover reasonable attorneys' fees and expenses if legal action is needed to enforce the amendment.
• · The Seller Affiliates Obligation to introduce clients to Dagley Insurance runs through May 2, 2028.
• · The service standard requires performance at a level of quality substantially similar to the prior 12 months.

06-07-2026

Churchill Capital Corp XI (CCXI), a SPAC, has entered into a promissory note agreement with its sponsor, Churchill Sponsor XI LLC, allowing for drawdowns of up to $1.5 million to fund working capital in connection with its initial business combination. The note is non-interest bearing and matures upon the earlier of the consummation of a business combination or the liquidation of the SPAC. The sponsor has waived any claims against the trust account, and the unpaid principal may be converted into units at $10.00 per unit at the sponsor's option.

• · The note is governed by New York law and includes a trust waiver preventing the sponsor from seeking recourse against the SPAC's trust account.
• · The note may be converted into units at the sponsor's option at a price of $10.00 per unit, with the units being identical to those issued in the private placement at IPO.
• · Holders of conversion units are entitled to up to three underwritten demands and piggyback registration rights under the existing Registration Rights Agreement dated December 16, 2025.
• · No interest accrues on the unpaid principal balance.

06-07-2026

Oragenics, Inc. held its Annual Meeting on June 29, 2026, where all six director nominees were re-elected and shareholders approved a non-binding advisory vote on executive compensation, a reverse stock split authorization (ratio between 1:2 and 1:50), and the ratification of Cherry Bekaert LLP as auditors. Additionally, the company appointed John Spencer, formerly Senior Controller, as Chief Financial Officer effective July 1, 2026, with a base salary of $200,000 and a $25,000 option award. While the reverse stock split authorization passed, it received significant opposition (836,159 against vs. 1,239,961 for), and the advisory vote on executive compensation showed notable dissent (478,522 against vs. 806,898 for).

• · John Spencer, age 32, joined Oragenics in April 2025 as Senior Controller and is a Certified Public Accountant in Florida.
• · The reverse stock split authorization passed with 1,239,961 for vs. 836,159 against, indicating notable shareholder opposition.
• · Advisory vote on executive compensation received 478,522 against vs. 806,898 for, with 24,545 abstentions and 793,522 broker non-votes.
• · Cherry Bekaert LLP was ratified as independent auditors with 1,887,381 for, 184,883 against, and 31,225 abstentions.
• · The Employment Agreement with John Spencer includes customary confidentiality, non-competition, and non-solicitation provisions.

06-07-2026

CISO Global, Inc. received a second 180-day compliance period from Nasdaq, extending the deadline to December 28, 2026, to regain the minimum $1.00 bid price requirement for continued listing. The company intends to cure the deficiency through a reverse stock split if necessary, but there is no assurance of compliance. The stock continues to trade on The Nasdaq Capital Market with no immediate impact.

• · Original compliance deadline was June 29, 2026; new deadline is December 28, 2026.
• · If a reverse stock split is implemented, it must be completed no later than ten business days before the expiration date.
• · The company must meet all other Nasdaq Capital Market listing requirements besides the bid price to remain eligible for the extension.
• · If compliance is not demonstrated by December 28, 2026, Nasdaq will issue a delisting notification, which can be appealed to a Hearings Panel.

06-07-2026

CytoSorbents Corp received a Nasdaq deficiency notice on June 29, 2026, for failing to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35 million for continued listing on the Nasdaq Capital Market. The company has a 180-day grace period until December 28, 2026, to regain compliance by achieving a market value of at least $35 million for 10 consecutive business days. While the notice does not trigger immediate delisting, the company faces significant risk of delisting if it cannot regain compliance, and management is evaluating potential actions including increasing stockholders' equity to at least $2.5 million.

• · The company may also consider increasing stockholders' equity to at least $2.5 million as an alternative path to regain compliance
• · If compliance is not achieved by December 28, 2026, the company will receive a delisting notification and may appeal the determination
• · The company's common stock trades on the Nasdaq Capital Market under the symbol CTSO

06-07-2026

IGC Pharma issued 4,274,853 shares of common stock to CEO Ram Mukunda and VP/PFO Claudia Grimaldi at $0.27 per share in exchange for cancellation of $1,154,210 in outstanding obligations, including personal cash advances and deferred amounts. The transaction reduced the Company's liabilities with no cash outlay and increased stockholders' equity, but resulted in significant dilution to existing shareholders.

• · The shares were issued at $0.27 per share, which may be below recent market price, indicating potential dilution.
• · The transaction was approved by independent directors and the Audit Committee with interested directors recused, complying with Rule 16b-3.
• · The shares are restricted securities and cannot be resold without registration or an exemption, and are subject to Section 16, insider trading policy, and NYSE American rules.
• · No underwriting discounts or commissions were paid, and no general solicitation was used.

06-07-2026

Empery Digital Inc. announced the early termination of its stockholder rights plan, with the Board approving an amendment to accelerate expiration to July 6, 2026, approximately seven months ahead of its original February 2, 2027 date. The Board determined the plan is no longer necessary to serve shareholder interests, though it may consider adopting a new plan in the future. The termination is administrative and has no effect on the company's common stock or Nasdaq listing.

• · Original rights plan expiration was February 2, 2027; accelerated to July 6, 2026
• · Company may consider adopting a new stockholder rights plan in the future
• · Termination actions are administrative with no effect on common stock or Nasdaq listing
• · Company employs a bitcoin treasury strategy focused on aggregating bitcoin and maximizing bitcoin per share

06-07-2026

Profusa, Inc. filed a Certificate of Amendment to effect a reverse stock split of its Common Stock at a ratio of 1-for-25, effective July 7, 2026. The Board was authorized to select a ratio between 1-for-5 and 1-for-200, and the CEO determined a 1-for-25 ratio. The amendment was adopted in accordance with Delaware law and aims to consolidate shares without changing par value.

• · The authorized range for the reverse split was 1-for-5 to 1-for-200; the actual ratio chosen by the CEO was 1-for-25.
• · The Certificate of Amendment becomes effective at 12:01 a.m. Eastern Time on July 7, 2026.
• · The amendment was signed on June 30, 2026, and filed under Delaware General Corporation Law Section 242.
• · Fractional shares will be eliminated, and adjustments will be made to outstanding convertible securities, warrants, and the 2025 Equity Incentive Plan.

06-07-2026

Timken Company entered into a Sixth Amended and Restated Credit Agreement dated July 2, 2026, replacing the prior Fifth Amended and Restated Credit Agreement from December 2022. The new facility is co-administered by Bank of America and JPMorgan Chase, with KeyBank and PNC as co-syndication agents, and includes a revolving credit facility with pricing tied to Timken's debt ratings (initially set at Pricing Level 3, BBB/Baa2). The agreement provides for borrowings in multiple currencies and includes customary representations, covenants, and events of default.

• · The agreement replaces the Fifth Amended and Restated Credit Agreement dated December 5, 2022.
• · Co-administrative agents: Bank of America, N.A. and JPMorgan Chase Bank, N.A.
• · Co-syndication agents: KeyBank National Association and PNC Bank, National Association.
• · Documentation agent: Wells Fargo Bank, National Association.
• · Paying agent for Non-EEA Agented Borrowers, L/C Issuer, and Swing Line Lender: JPMorgan Chase Bank, N.A.
• · Paying agent for EEA Agented Borrowers: J.P. Morgan SE.
• · Joint lead arrangers and joint bookrunners: BofA Securities, Inc., JPMorgan Chase Bank, N.A., KeyBanc Capital Markets Inc., and PNC Capital Markets LLC.
• · Initial pricing set at Pricing Level 3 (BBB/Baa2) with an Applicable Rate of 1.015% for Term SOFR loans and a facility fee of 0.110%.
• · The agreement includes provisions for borrowings in multiple currencies (Committed Currencies) and allows for Designated Borrowers (subsidiaries).
• · Financial covenants are referenced in Section 8.11 but not detailed in the excerpt.
• · The agreement includes standard representations, affirmative and negative covenants, and events of default.

06-07-2026

RxSight announced a non-exclusive collaboration with Alcon to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs) combining RxSight's light-adjustable technology with Alcon's PCIOL optical designs. RxSight will receive a $60 million upfront payment and up to $140 million in development and regulatory milestones, plus royalties on net sales, while Alcon will lead global commercialization. The collaboration is a significant validation of RxSight's platform but involves no guaranteed revenue beyond the upfront payment and carries typical development and regulatory risks.

• · Collaboration is non-exclusive, allowing RxSight to potentially partner with others.
• · RxSight will be responsible for development and manufacturing; Alcon leads commercialization.
• · RxSight will receive royalties on net sales, but royalty rates are not disclosed.
• · The agreement covers novel post-operative light adjustable PCIOL technologies, not RxSight's existing LAL products.
• · Alcon is described as the global leader in eye care with a heritage spanning over 75 years.

06-07-2026

Fortress Net Lease REIT increased its credit facilities by $100 million to an aggregate $1.9 billion, adding Regions Bank as a new lender. The revolving credit facility grew from $1.475 billion to $1.545 billion, and the term loan facility increased from $325 million to $355 million. The expansion strengthens the REIT's liquidity without triggering repayment obligations.

06-07-2026

Agenus Inc. entered into an amendment with existing noteholders to extend the maturity of $5.09M in 2015 senior subordinated promissory notes by eight months to February 18, 2027, and extended the expiration of previously issued warrants (2022 A, 2022 B, and 2025 C) to June 25, 2031. The company also issued new 2026 D Warrants to purchase 56,525 shares at $3.25 per share, expiring June 25, 2031, with a commitment to register the underlying shares for resale within 90 days. The amendment provides near-term liquidity relief but dilutes existing shareholders through the issuance of additional warrants.

• · The 2015 Notes' interest rate and all other terms remain unchanged.
• · The New D Warrants and underlying shares are unregistered and issued under Section 4(2) exemption.
• · No commission or remuneration was paid for soliciting the issuance.
• · The company must file a resale registration statement for the New D Warrant shares within 90 days after June 29, 2026.

06-07-2026

Neutron Holdings, Inc. (Lime) entered into a Credit Agreement dated July 2, 2026, with JPMorgan Chase Bank, N.A. as Administrative Agent, and JPMorgan, Citizens Bank, and Goldman Sachs as Joint Lead Arrangers and Bookrunners. The agreement provides revolving credit facilities and letters of credit, with borrowing costs tied to the Total Net Leverage Ratio. Key terms include mandatory prepayments from certain asset sales, debt incurrence limits, and negative covenants restricting investments, dividends, and subsidiary liens.

• · No financial covenant thresholds (maximum leverage, minimum liquidity) are disclosed in the filing excerpt.
• · The Credit Agreement includes a right-to-cure provision (Section 6.12) but the details are not excerpted.
• · Negative covenants cover restricted payments, investments, affiliate transactions, and sale-leaseback transactions, among others.
• · The agreement incorporates standard 1.00% per annum floor for the Alternate Base Rate.
• · Post-closing requirements and existing indebtedness schedules are referenced but not included.

06-07-2026

Dell Technologies Inc. filed an 8-K on July 6, 2026, disclosing amendments to its Bylaws effective July 12, 2026, which modify provisions related to shareholder meetings, director nominations, and shareholder business proposals. The amendments include updated advance notice requirements for shareholder proposals and nominations, as well as adjustments to special meeting calling thresholds and meeting procedures. The filing does not contain any financial results or quantitative performance data.

• · The amended Bylaws are effective July 12, 2026.
• · Special meetings may be called by holders of not less than 50% of voting power (or the highest percentage specified in the TBOC).
• · Advance notice for shareholder nominations or business at annual meetings must be delivered between 90 and 120 days prior to the anniversary of the prior year's annual meeting, with adjustments if the meeting date is advanced by more than 30 days or delayed by more than 70 days.
• · Shareholder notices must include detailed information about the proposing shareholder, beneficial owners, and any agreements related to the nomination or proposal.
• · The filing references the MD Shareholders Agreement and SLP Shareholders Agreement, both dated July 2, 2026 (amending prior agreements from December 25, 2018).

06-07-2026

Professional Diversity Network, Inc. (IPDN) entered into a Stock Purchase Agreement on July 2, 2026, to sell its wholly-owned subsidiaries NAPW, Inc. and IAW, Inc. to MEB Holding LLC for $150,000. The transaction closed on July 3, 2026, and the board of directors approved the sale on the same day. The sale represents a significant corporate restructuring, potentially indicating a shift in strategy or reduction of assets, though the low purchase price may imply limited value or liabilities in the subsidiaries.

• · The transaction was effective for accounting and economic purposes as of June 30, 2026.
• · The shares were sold in reliance on the exemption from registration under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D.
• · The Seller owned 100% of the outstanding shares of both NAPW, Inc. and IAW, Inc.

06-07-2026

Splash Beverage Group (SBEVW) entered an exclusive worldwide license agreement with Argent Biopharma Limited for CannEpil®, a cannabinoid-based treatment for epilepsy and seizure disorders. The company issued 5,500 shares of Series D Convertible Preferred Stock (total stated value $5.5M) and secured a $1M investment commitment from C/M Capital Partners to support commercialization. However, the license is early-stage: the company must initiate Phase I clinical trials within 24 months and obtain FDA approval within five years, with a 15% royalty on net sales payable to the licensor.

• · License initial term is 20 years, with automatic 5-year renewals unless 12-month non-renewal notice is given.
• · Conversion price for Series D is $0.25 per share, subject to downward adjustment with a floor of $0.15 per share.
• · Series D carries a 4.99% beneficial ownership limitation (can be increased to 9.99% upon 61 days' notice).
• · No financial statements were included in the filing (Item 9.01 only lists exhibits).
• · The license requires the company to file a New Drug Application with the FDA within a commercially reasonable time after successful clinical trials.

06-07-2026

XMax Inc. approved salary increases and amendments to employment agreements for its CEO, COO, and CFO, effective July 1, 2026. CEO Xiaohua Lu's salary doubled from $80,000 to $160,000, COO Yizhou Zhao's rose from $80,000 to $159,000, and CFO Jeffery Chuang's increased from $70,000 to $80,000. The changes were approved by the Compensation Committee and Board, with no other terms modified.

• · Salary increases effective July 1, 2026
• · Approved by Compensation Committee and Board of Directors
• · Form of Amendment filed as Exhibit 10.1

06-07-2026

Twin Disc, Inc. entered into a new $90M credit facility on June 30, 2026, comprising a $30M term loan and a $60M revolving credit facility, with Bank of Montreal and JPMorgan Chase as lenders. The facility refinances the prior credit agreement from February 2025 and matures on June 30, 2031. The company also granted security interests over substantially all personal property and pledged 65% of equity in certain foreign subsidiaries.

• · The Credit Agreement refinances and replaces the prior credit agreement dated February 14, 2025.
• · Interest rates are based on SOFR, EURIBO Rate, CORRA, or Base Rate, with Applicable Margins ranging from 1.50% to 3.00% for Loans and 0.15% to 0.30% for the Unused Revolving Credit Commitment.
• · Security includes substantially all personal property (accounts receivable, inventory, machinery, IP) and 65% of equity in certain foreign subsidiaries.
• · Upon an Event of Default (other than bankruptcy), the Administrative Agent may terminate commitments, accelerate all loans, and demand cash collateralization of L/C Obligations at 105%.
• · The filing includes multiple ancillary agreements: Amended and Restated Security Agreement, IP Security Agreement, Pledge Agreement, Perfection Certificate, Agreement as to Liens and Encumbrances, and Negative Pledge Agreement.

06-07-2026

ClearOne (CLRO) entered into a definitive merger agreement to acquire Cortigent, Inc., a wholly-owned subsidiary of Vivani Medical (VANI), in a reverse merger transaction. Cortigent develops brain implant devices for vision restoration and stroke recovery, and its Orion system has FDA Breakthrough Device Designation. The deal will result in Vivani owning 59.4% to 67.5% of the combined company, while former ClearOne shareholders will own only 12.7% to 14.4%, representing significant dilution. The transaction is expected to close in Q3 2026, subject to a concurrent financing of $10M-$15M and other conditions.

• · ClearOne has recently divested its former conferencing, collaboration, and network streaming business, leaving it as a public shell.
• · The combined company will be renamed 'Cortigent Holdings, Inc' and trade under ticker 'CRGT'.
• · Cortigent's Orion system completed a 6-year early feasibility study in 2025 with promising tolerability and clinical activity results.
• · The transaction is subject to customary closing conditions including stockholder approvals, minimum net cash requirements, and Nasdaq continued listing.
• · ThinkEquity acted as sole financial advisor to the transaction.

06-07-2026

Targa Resources Corp. subsidiary Targa Resources Partners LP and its bankruptcy-remote special purpose entity Targa Receivables LLC entered into a Seventeenth Amendment to the Receivables Purchase Agreement on July 1, 2026, extending the facility termination date to July 30, 2027 and establishing an uncommitted line of $200 million. As of the amendment date, approximately $451 million of trade receivable purchases were outstanding under the facility. The amendment reflects routine refinancing activity with no material change in the company's financial position.

• · The amendment is the seventeenth amendment to the original Receivables Purchase Agreement dated January 10, 2013.
• · The facility is an accounts receivable securitization facility involving conduit purchasers, committed purchasers, purchaser agents, and letter of credit participants.
• · The committed purchasers or their affiliates have performed investment banking, financial advisory, and commercial banking services for the company and its affiliates, receiving customary compensation.

06-07-2026

Cloudastructure, Inc. (CSAI) entered into an Exchange Agreement with Streeterville Capital, LLC on June 30, 2026, exchanging 1,170 shares of Series 2 Convertible Preferred Stock for a Promissory Note with an original principal amount of $1,299,870. The exchange is intended to comply with Section 3(a)(9) of the Securities Act and does not involve any new cash consideration to the company. The Series 2 Preferred Stock was originally issued under a Securities Purchase Agreement dated March 21, 2025, which allowed for up to $40,000,000 in purchases.

• · The Exchange Note is intended to tack the holding period of the Series 2 Shares from December 15, 2025, for Rule 144 purposes.
• · The Exchange Agreement does not constitute a novation or satisfaction of the Series 2 Shares; the obligations are merely restructured.
• · The Purchase Agreement remains in full force and effect until the Exchange Note is paid in full.
• · No Event of Default under the Series 2 Preferred Stock has been waived by the Investor.
• · The Company received no consideration other than the surrender of the Series 2 Shares.

06-07-2026

On July 6, 2026, Optimum Communications, Inc. (through its subsidiaries Cablevision of Litchfield, LLC and CSC Optimum Holdings, LLC) entered into a Second Amended and Restated Credit Agreement with lenders led by JPMorgan Chase, consolidating prior facilities and adding a new $250.0 million second incremental term loan. The agreement aggregates total committed credit of up to $3.35 billion across three tranches: $2.0 billion initial term loans (November 2025), $1.1 billion incremental term loans (January 2026), and the new $250.0 million second incremental tranche. The facility is secured and includes customary affirmative and negative covenants, with leverage ratio triggers for amortization periods.

• · Original Credit Agreement dated November 25, 2025; A&R Credit Agreement dated January 12, 2026; Amendment No. 1 effective May 29, 2026.
• · The Second Amended and Restated Credit Agreement becomes effective on the Second Incremental Closing Date (July 6, 2026) per Section 4.05.
• · Borrower Representative is Cablevision of Litchfield, LLC; co-borrower is CSC Optimum Holdings, LLC.
• · The agreement includes provisions for an ABS Loan Agreement (Receivables Facility dated July 16, 2025) and intercreditor arrangements.

06-07-2026

Landstar System, Inc. entered into a Third Amended and Restated Credit Agreement dated June 30, 2026, amending and restating its existing credit facility. The agreement extends the maturity date and re-evidences outstanding obligations, with JPMorgan Chase Bank, N.A. serving as Administrative Agent. No specific financial amounts or changes in borrowing capacity are disclosed in the filing.

• · The agreement amends and restates the Second Amended and Restated Credit Agreement dated July 1, 2022, as amended June 21, 2024.
• · The agreement is among Landstar System Holdings, Inc. (Borrower), Landstar System, Inc. (Parent), subsidiary guarantors, and multiple lenders.
• · Co-syndication agents are Bank of America, N.A., Wells Fargo Bank, National Association, and Truist Bank.
• · JPMorgan Chase Bank, N.A. acts as Sole Lead Arranger and Sole Bookrunner.

06-07-2026

Zoomcar Holdings, Inc. completed the third closing of its private placement on June 30, 2026, issuing 195 Series A Units at $1,000 per Unit for gross proceeds of approximately $195,000. The offering, which can total up to $10 million including an overallotment option, also involved extending CEO Deepankar Tiwari's consultancy agreement through May 9, 2027. However, the $195,000 raised in this closing is modest relative to the $5 million base offering target, and the company remains an emerging growth company with no securities registered under Section 12(b) of the Exchange Act.

• · The Offering is scheduled to terminate on July 30, 2026, unless extended by the Company.
• · Subscription amounts were held in escrow with CSC Delaware Trust Company pending the Third Closing.
• · The Warrants expire five years from the date of issuance.
• · The Registration Rights Agreement requires the Company to file a resale registration statement within 15 calendar days after the Third Closing and to use best efforts to have it declared effective.
• · The Company is relying on exemptions under Section 4(a)(2) of the Securities Act and Rule 506(c) of Regulation D for the unregistered sale of securities.
• · The Placement Agent's exclusive engagement term ended on June 30, 2026, upon completion of the Third Closing.
• · The Amendment to the Consultant Agreement with Deepankar Tiwari was dated June 10, 2026, extending his term from May 9, 2026 to May 9, 2027.

06-07-2026

Sky Harbour Group Corp (SKYH-WT) entered into a Second Amendment to its Draw Down Note Purchase and Continuing Covenant Agreement with JPMorgan Chase Bank, N.A. as Administrative Agent, effective June 29, 2026. The amendment allows for a special borrowing of up to $20,000,000 to finance the OPF II Project at Opa Locka Airport, with the condition that the sponsor must replenish equity by contributing at least $20,000,000 within 90 days, expected to come from proceeds of $150,000,000 in Series 2026 Public Finance Authority Revenue Bonds. However, until the equity replenishment conditions are satisfied, the company cannot request further borrowings for Borrowing Base Projects and must maintain a negative pledge on its SJC Project in San Jose, California.

• · The OPF II Borrowing is limited to financing or reimbursing costs of the OPF II Project at Opa Locka Airport, with a deadline of December 31, 2026.
• · The OPF II Project Owner is not a Borrower, and the OPF II Project is not included in the Borrowing Base.
• · Until equity replenishment conditions are met, the Borrowers cannot request any Borrowing or Loan for Borrowing Base Projects, except for loans funding capitalized interest, fees, and reserves.
• · The SJC Project Entities (including SJC Hangars and SKYH National) are subject to a negative pledge restricting liens, dispositions, pledges of equity, and incurrence of secured or recourse indebtedness until equity replenishment conditions are satisfied.
• · The amendment also requires delivery of a sponsor/guarantor guaranty for the equity replenishment obligation, along with legal opinions and closing certificates.

06-07-2026

Public Company Management Corp (PCMC) has entered into a Share Exchange Agreement to acquire all outstanding shares of Physicians Capital Management Corporation from its stockholders, including Dr. Conrad Ivie. In exchange, PCMC will issue 68,566,368 shares of Common Stock and 24,913,918 shares of Preferred Stock (Series A, B-1, and B-2), representing approximately 80% of PCMC's fully diluted shares post-closing. The transaction also includes the issuance of 3,750,000 Series B-1 shares to Specialty Capital Lenders LLC to satisfy outstanding notes, and grants Dr. Ivie voting control via Series A Preferred Stock.

• · Series B-1 shares are convertible into Common Stock at a ratio of 4:1 after 18 months from closing.
• · Series B-2 shares are convertible into Common Stock at a ratio of 8:1 after 24 months from closing.
• · Employee Stockholders will receive only PCMC Common Stock, not Preferred Stock.
• · The aggregate Exchange Shares are fixed; any shares issued to Employee Stockholders reduce only Ivie's allocation.
• · The transaction includes a Lock-Up Agreement for certain stockholders, but Repository Services LLC and its transferees are exempt.
• · A Registration Statement on Form S-4 will be filed to register the Common Stock portion of the Exchange Shares.

06-07-2026

P3 Health Partners Inc. amended a repurchase promissory note with IHC Health Services, Inc., extending the maturity date to September 30, 2028, and increasing the interest rate to 14% per annum (paid-in-kind). The amendment reflects a significant increase in borrowing cost and a longer repayment timeline, indicating potential liquidity pressure.

• · The original note was dated June 28, 2019, and was previously amended on November 19, 2020.
• · The note is held by IHC Health Services, Inc., a related party (IHC is likely Intermountain Health Care).
• · The amendment was entered into by a wholly owned subsidiary, P3 Health Group, LLC.
• · No principal amount or outstanding balance of the note was disclosed in the filing.

06-07-2026

Semtech Corporation entered into a new Credit Agreement dated July 6, 2026, with Morgan Stanley Senior Funding, Inc. as Administrative Agent and Swing Line Lender, and a syndicate of lenders including UBS, BMO, HSBC, U.S. Bank, Wells Fargo, Barclays, JPMorgan, RBC, and Silicon Valley Bank. The facility provides revolving credit and incremental term loan commitments to refinance the existing credit agreement, fund transaction costs, permitted acquisitions, investments, and general corporate purposes. The agreement includes financial covenants, negative covenants, and events of default, and references the company's existing 2027 Convertible Notes (1.625% due November 2027) and 2030 Convertible Notes (0% due October 2030).

• · The Credit Agreement includes provisions for Additional Revolving Credit Commitments and Incremental Term Loans, allowing for future increases in borrowing capacity.
• · Interest rates are based on Adjusted Term SOFR Rate, Adjusted EURIBOR Rate, Adjusted TIBOR Rate, or Adjusted Daily Simple RFR, each with a floor (minimum rate).
• · The agreement contains negative covenants including restrictions on Liens, Investments, Indebtedness, Fundamental Changes, Dispositions, Restricted Payments, and Transactions with Affiliates.
• · Financial covenants are referenced in Section 7.15 but specific ratios or thresholds are not disclosed in the excerpt.
• · The agreement includes standard events of default, remedies, and provisions for cash collateral, extension offers, and refinancing facilities.

06-07-2026

Clarivate PLC, through its subsidiaries, has entered into a Stock and Asset Purchase Agreement dated July 3, 2026, to sell certain assets and interests of its business to Janus Buyer, LP, an entity backed by Altaris Health Partners. The base purchase price is $600,000,000, subject to customary adjustments. The transaction involves a pre-closing restructuring and includes the transfer of intellectual property, IT assets, and employees, with closing conditions including regulatory approvals and other customary covenants.

• · The agreement includes a Guarantee from Altaris Health Partners VI, L.P. and Altaris Health Partners VI-A, L.P. for Buyer's obligations.
• · The transaction involves the sale of both stock and assets, with specific definitions for Assigned Intellectual Property Rights, Assigned IT Assets, and Assigned Software Applications.
• · The agreement includes detailed provisions for employee matters, tax matters, and indemnification, with a survival period for representations and warranties.
• · The closing is subject to conditions including regulatory approvals, absence of material adverse effect, and accuracy of representations.

06-07-2026

Element Solutions Inc. (ESI) has entered into a definitive Agreement and Plan of Merger with Solstice Advanced Materials Inc. (Parent) on July 6, 2026, under which ESI will be acquired through a two-step merger process. The transaction is structured as a tax-free reorganization, with ESI stockholders receiving Parent stock and certain ESI stockholders entering into voting and support agreements. The closing is expected to occur after regulatory and stockholder approvals, with Parent's board to be expanded to 11 directors including three Designated Directors from ESI.

• · The merger is structured as two sequential mergers: First Merger (Merger Sub One merges into ESI) and Second Merger (surviving corporation merges into Merger Sub Two).
• · The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the Code.
• · Parent may delay closing to January 4, 2027 if the closing condition satisfaction date occurs after December 6, 2026 and before January 1, 2027.
• · Certain ESI stockholders have executed voting and support agreements in favor of Parent concurrently with the agreement.
• · The Parent board will be expanded to 11 directors, with 3 Designated Directors from ESI becoming Class I or Class II directors.

06-07-2026

American Bitcoin Corp. (ABTC) filed a Certificate of Amendment to effect a 1-for-15 reverse stock split of its Class A, Class B, and Class C Common Stock, effective upon filing. The amendment was approved by the Board and stockholders, and fractional shares will be aggregated and sold for cash. This action reduces the outstanding share count but does not change the company's underlying business or financial performance.

• · The reverse stock split applies to all three classes of common stock (Class A, Class B, Class C) at the same 1-for-15 ratio.
• · No fractional shares will be issued; fractional interests will be aggregated, sold, and distributed as cash pro rata.
• · The amendment was filed on July 2, 2026, and became effective upon filing with the Delaware Secretary of State.
• · The company has undergone multiple name changes: originally MTech Acquisition Holdings Inc., then Akerna Corp., then Gryphon Digital Mining, Inc., and now American Bitcoin Corp.

06-07-2026

Vertex Pharmaceuticals (VRTX) has agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85.00 per share in cash, representing a total equity value of approximately $10.0 billion ($8.8 billion net of estimated cash acquired). The deal adds Crinetics' recently launched once-daily oral acromegaly therapy PALSONIFY® and Phase 3 ACTH receptor antagonist atumelnant for congenital adrenal hyperplasia (CAH), with combined peak sales potential of ~$5 billion. The transaction, unanimously approved by both boards, is expected to close in Q3 2026 and immediately contribute to Vertex's revenue growth, though it is not expected to become accretive to non-GAAP operating income until 2029.

• · PALSONIFY was approved by the FDA in September 2025 and recently approved by the EMA; it is under review by other global regulatory bodies.
• · Paltusotine is also in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors.
• · Atumelnant is in Phase 3 development for CAH and Phase 1/2b for ACTH-dependent Cushing's syndrome.
• · The transaction is expected to become accretive to non-GAAP operating income in 2029.
• · Vertex expects to finance the acquisition using cash on hand and debt, supported by $4.5 billion of fully committed bridge financing.
• · Crinetics has 10+ disclosed programs including CRN09682, a nonpeptide drug conjugate candidate for SST2-expressing tumors.

06-07-2026

Polar Power, Inc. (POLA) received a Nasdaq deficiency letter on May 1, 2026 for failing to meet the minimum stockholders' equity requirement of $2.5 million under Listing Rule 5550(b), reporting only $144,000 in stockholders' equity as of December 31, 2025. The company submitted a compliance plan on June 15, 2026, and on June 29, 2026, Nasdaq granted an extension until October 28, 2026 to regain compliance through either a public filing evidencing a completed transaction or a pro forma balance sheet. However, if the company fails to demonstrate compliance by its next periodic report for the year ending December 31, 2026, it may face delisting.

• · The company must comply by October 28, 2026, choosing between two alternatives: (A) filing a public report with disclosure of the deficiency, description of the completed transaction, and an affirmative statement of regained compliance; or (B) filing a public report with a pro forma balance sheet no older than 60 days evidencing compliance.
• · If the company fails to evidence compliance upon filing its periodic report for the year ending December 31, 2026, it may be subject to delisting.
• · The company may appeal a delisting determination to a Hearings Panel.